# Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension

> **NCT01122251** · PHASE2 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 441 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Lercanidipine + Valsartan
- **DRUG:** Lercanidipine or Valsartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01122251
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-05
- **Final completion:** 2010-07
- **Target enrollment:** 441 (ESTIMATED)
- **Last updated:** 2011-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01122251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01122251, "Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01122251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*